Clinical Trial Update: Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and tolerability of Rituximab (MabThera) in Bullous Pemphigoid has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bullous Pemphigoid

Drugs mentioned

• MabThera (rituximab)

Snippet

Sponsor: University Hospital, Rouen | Conditions: Bullous Pemphigoid | Phase 3 | Status: COMPLETED